Gefitinib paradoxically activates ERK1/2 in NSCLC cells bearing wild-type EGFR but not a drug-resistant mutant form after 6 h of incubation. (A–F) Western blot analysis. Exponentially growing H-1838 cells (A and B; EGFR wild-type EGFR), H-2170 cells (C and D; EGFR wild-type), and H-1975 cells (E and F; T790M + L858R TKI-resistance mutant form of EGFR) cells were treated with various concentration of gefitinib and collected after 1 h (A, C, and E) and 6 h (B, D, and F) h of treatment.